Patel, J. N., Jiang, C., Hertz, D. L., Mulkey, F., Friedman, P. N., Halabi, S., … McLeod, H. L. (2014). Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE). In Journal of Clinical Oncology (Vol. 32, pp. e16061–e16061). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.e16061

Patel, Jai Narendra, Chen Jiang, Daniel Louis Hertz, Flora Mulkey, Paula N. Friedman, Susan Halabi, Mark J. Ratain, et al. “Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).” In Journal of Clinical Oncology, 32:e16061–e16061. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e16061.

Patel JN, Jiang C, Hertz DL, Mulkey F, Friedman PN, Halabi S, et al. Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. e16061–e16061.

Patel, Jai Narendra, et al. “Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. e16061–e16061. Crossref, doi:10.1200/jco.2014.32.15_suppl.e16061.

Patel JN, Jiang C, Hertz DL, Mulkey F, Friedman PN, Halabi S, Ratain MJ, Morris MJ, Small EJ, Owzar K, Kelly WK, McLeod HL. Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. e16061–e16061.